Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 6/20 | 0.34 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | CTSD | P07339 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.34 |
| ▸ | HPD | P32754 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661865 | 0.87 | SCN9A (0.48) | SCN9A | |
| SCHEMBL5658582 | 0.86 | PDE10A (0.34) | SCN9ACHRM5OPRL1EDNRBEDNRA | |
| SCHEMBL5659353 | 0.84 | ALDH1A1 (0.40) | — | |
| SCHEMBL5659844 | 0.83 | OPRL1 (0.33) | OPRL1EDNRBEDNRAPDE10ANPY5R | |
| SCHEMBL5660992 | 0.82 | OPRL1 (0.35) | CHRM5OPRL1EDNRBEDNRACCKBR | |
| SCHEMBL5661607 | 0.82 | OPRL1 (0.33) | OPRL1EDNRBEDNRANPY5RCCKBR | |
| SCHEMBL5659652 | 0.80 | CETP (0.34) | OPRL1EDNRBEDNRACCKBRCETP | |
| SCHEMBL5656443 | 0.75 | MAPT (0.44) | SCN9A | |
| SCHEMBL14457630 | 0.75 | SCN9A (0.43) | SCN9A | |
| SCHEMBL5660687 | 0.74 | AR (0.46) | NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250442-B2 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2005-03-10 | — | — | US | disclosed |
| EP-1487792-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003078394-A1 | DIHYDROINDOL-2-ONE DERIVATIVES AS STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054712-A1 | Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators | NR3C2, NR5A1, NR5A2 | SCN9A 1918/4885CHRM5 1591/4885OPRL1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.